Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination

References

• Vezina C, Kudelski A, Sehgal S N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28: 721–726
   PubMed Web of Science ®Google Scholar
• Panwalkar A, Verstovsek S, Giles F J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004; 100: 657–666
   PubMed Web of Science ®Google Scholar
• Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006; 17: 487–494
   PubMed Web of Science ®Google Scholar
• Chan S, Scheulen M E, Johnston S, Mross K, Cardoso F, Dittrich C, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23: 5314–5322
   PubMed Web of Science ®Google Scholar
• Atkins M B, Hidalgo M, Stadler W M, Logan T F, Dutcher J P, Hudes G R, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909–918
   PubMed Web of Science ®Google Scholar
• Witzig T E, Geyer S M, Ghobrial I, Inwards D J, Fonseca R, Kurtin P, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347–5356
   PubMed Web of Science ®Google Scholar
• Reeder C B, Gormet M K, Habermann T M, Ansell S M, Micallef I N, Porrata L F, et al. A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive Non-Hodgkin lymphoma (NHL). [Abstract]. Blood 2007; 110: 121
   Web of Science ®Google Scholar
• Rizzieri D A, Feldman E, Dipersio J F, Gabrail N, Stock W, Strair R, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008; 14: 2756–2762
   PubMed Web of Science ®Google Scholar
• Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol 2008; Aug 14, [Epub ahead of print]
   Google Scholar
• Yee K W, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12: 5165–5173
   PubMed Web of Science ®Google Scholar
• Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992; 50: 177–185
   PubMed Web of Science ®Google Scholar
• Csoka K, Larsson R, Tholander B, Gerdin E, de la Torre M, Nygren P. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 1994; 54: 163–170
   PubMed Web of Science ®Google Scholar
• Dhar S, Nygren P, Csoka K, Botling J, Nilsson K, Larsson R. Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer 1996; 74: 888–896
   PubMed Web of Science ®Google Scholar
• Rickardson L, Fryknas M, Haglund C, Lovborg H, Nygren P, Gustafsson M G, et al. Screening of an annotated compound library for drug activity in a resistant myeloma cell line. Cancer Chemother Pharmacol 2006; 58: 749–758
   PubMed Web of Science ®Google Scholar
• Fitzgerald J B, Schoeberl B, Nielsen U B, Sorger P K. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006; 2: 458–466
   PubMed Web of Science ®Google Scholar
• Grabovsky Y, Tallarida R J. Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J Pharmacol Exp Ther 2004; 310: 981–986
   PubMed Web of Science ®Google Scholar
• Datta S R, Brunet A, Greenberg M E. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905–2927
   PubMed Web of Science ®Google Scholar
• David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004; 10: 6865–6871
   PubMed Web of Science ®Google Scholar
• Zhou X, Tan M, Stone Hawthorne V, Klos K S, Lan K H, Yang Y, et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004; 10: 6779–6788
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Pallet N, Rabant M, Marquet P, Cassinat B, Meria P, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006; 70: 1019–1025
   PubMed Web of Science ®Google Scholar
• Pawarode A, Shukla S, Minderman H, Fricke S M, Pinder E M, O'Loughlin K L, et al. Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother Pharmacol 2007; 60: 179–188
   PubMed Web of Science ®Google Scholar
• Grunwald V, DeGraffenried L, Russel D, Friedrichs W E, Ray R B, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002; 62: 6141–6145
   PubMed Web of Science ®Google Scholar
• Stromberg T, Dimberg A, Hammarberg A, Carlson K, Osterborg A, Nilsson K, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 2004; 103: 3138–3147
   PubMed Web of Science ®Google Scholar
• Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam R W, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10: 331–342
   PubMed Web of Science ®Google Scholar
• Mondesire W H, Jian W, Zhang H, Ensor J, Hung M C, Mills G B, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004; 10: 7031–7042
   PubMed Web of Science ®Google Scholar
• Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas V M, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105: 2527–2534
   PubMed Web of Science ®Google Scholar